Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
Holding DE:4AB?
Track your performance easily
4AB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€125.50 - €192.50
Previous Close€162.74
Volume36.00
Average Volume (3M)795.00
Market Cap
€289.83B
Enterprise Value€350.05B
Total Cash (Recent Filing)$7.29B
Total Debt (Recent Filing)$71.08B
Price to Earnings (P/E)61.6
Beta0.04
Next Earnings
Jan 29, 2025EPS Estimate
€2.8Next Dividend Ex-Date
Jan 15, 2025Dividend Yield3.69%
Share Statistics
EPS (TTM)2.64
Shares Outstanding1,767,140,323
10 Day Avg. Volume2,361
30 Day Avg. Volume795
Standard Deviation0.07
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)46.38
Price to Sales (P/S)5.30
Price to Cash Flow (P/CF)13.50
P/FCF Ratio12.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.30
Enterprise Value/Gross Profit10.33
Enterprise Value/Ebitda19.23
Forecast
1Y Price Target
€196.57Price Target Upside14.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
AbbVie News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAbbVie reported solid 3Q results driven by Skyrizi/Rinvoq and oncology portfolio beats, and raised 2024 revenue guidance to $56B.
Growth OutlookABBV is still well positioned with no major loss of exclusivity until the 2030s, and has a number of growth drivers highlighted by Skyrizi and Rinvoq.
Product PortfolioAbbVie's newer agents, Skyrizi and Rinvoq, are offsetting the volume declines of Humira and are gaining prescriber preference over biosimilars.
Bears Say
Clinical TrialsAbbVie announced that emraclidine’s pivotal Phase 2 trials did not meet their primary endpoints.
Earnings ForecastAbbVie is now guiding for more erosion in Humira sales than before, lowering guidance to $9.2B from $9.6B.
Market PerformanceThe emraclidine setback has caused a significant drop in market cap, with a loss of about $55 billion since the emraclidine miss.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
22.03% Mutual Funds
15.14% Other Institutional Investors
41.39% Public Companies and
Individual Investors
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €125.50 and its highest was €192.50 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jan 29, 2025 which is in 67 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Oct 30, 2024. The company reported €2.83 earnings per share for the quarter, beating the consensus estimate of €2.755 by €0.075.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €1.55 which represents an annual dividend yield of 3.69%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is €2.8.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,140,400 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.83 in its last earnings report, beating expectations of €2.755. Following the earnings report the stock price went up 4.067%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 260M.
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€196.57 (14.87% Upside)
€196.57 (14.87% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 94%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.31%
12-Months-Change
Fundamentals
Return on Equity
56.06%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
4AB Earnings Call
Q3 2024
0:00 / 0:00
---
4AB Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
4AB Stock 12 Month Forecast
Average Price Target
€196.57
▲(14.87% Upside)
Technical Analysis
Best Analysts Covering 4AB
1 Year
1 Year Success Rate
20/23 ratings generated profit
1 Year Average Return
+17.90%
reiterated a buy rating 12 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +17.90% per trade.
---